BioSpace News Archive

The first interim analysis of a three-arm Phase II ARC-7 trial shows Arcus Biosciences’ anti-TIGIT immunotherapy combination features “encouraging clinical activity” as an initial therapy for patients with metastatic non-small cell lung cancer (NSCLC).

Fulcrum achieved what the company is calling a clinical first. Data showed that using losmapimod slowed the progression of FSHD and demonstrated improved function in patients.

Vida Ventures III will approach investments the same way its first two funds do, identifying and investing in what they believe to be transformative biomedical innovative companies.

A new outside evaluation concludes that the UltraDrape™ Barrier and Securement Dressing makes it easier for clinicians to adhere to the principles of Aseptic Non Touch Technique for PIV insertions using ultrasound.

Spruce Biosciences, Inc. today announced the appointment of Kirk Ways, M.D., Ph.D., to its board of directors.

Neurent Medical today announced expansions of its leadership team.

Pieris Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to cinrebafusp alfa (PRS-343), a 4-1BB/HER2 bispecific, for the treatment of HER2-high and HER2-low expressing gastric cancers.

Anova continues to provide a transformative approach for doctors to access promising new treatments for patients.

IM Therapeutics, Inc. announced today that Peter Gottlieb, M.D., Co-founder and Chief Medical Officer, will present at the American Diabetes Association (ADA) 81 st Scientific Sessions, held June 25-29, 2021.

– Phase 1b expansion cohorts designed to enable refinement of recommended Phase 2 dose – – At least 12 patients to be enrolled in each of two Phase 1b expansion cohorts: a 200 mg dose cohort and a 600 mg dose cohort – – Each cohort to be genetically enriched with NPM1-mutant and KMT2A-rearranged relapsed/refractory AML patients.